RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

Phase 2

Completed

Conditions: Venous Thromboembolism
Menstruation

Interventions: Drug: Apixaban
Drug: Rivaroxaban

Registration Number: NCT02829957

Lead Sponsor: Indiana University

Brief Summary: A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.

Detailed Description: Heavy menstrual bleeding (HMB) complicates the treatment of approximately 9-25% of patients treated with orally administered anti-Xa anticoagulants for venous thromboembolism (VTE, including either pulmonary embolism or deep vein thrombosis). In particular, recent evidence has suggested an increase in length and severity of menstrual bleeding for women treated with rivaroxaban, and this effect may be less severe apixaban treatment.(1;2) Increase in uterine bleeding with rivaroxaban has necessitated hysterectomy in rare cases.(3) Other complications of HMB include reduced drug adherence, decreased perception of wellness (quality of life) and anemia.(4;5) The anti-Xa agents may increase HMB more than vitamin K antagonists.(1) However, in the principal investigators' experience treating over 100 women of menstruating age with rivaroxaban for VTE with varying degree of HMB, no woman has expressed desire to switch to a VKA even when offered this option (unpublished data). We have successfully reduced perception of HMB by switching from rivaroxaban to apixaban in six patients. Comparison of published and supplemental data from AMPLIFY and AMPLIFY Extend to EINSTEIN and EINSTEIN extend trials also support a lower rate of uterine bleeding with apixaban compared with rivaroxaban, although exact comparisons are difficult to make.(6;9) Myers et al recently reported a 9.4% rate of HMB with apixaban, compared with a 25% rate of HMB with rivaroxaban.(2) Accordingly, we hypothesize that women with menstruating potential with newly diagnosed VTE or atrial fibrillation/flutter, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 19

Inclusion Criteria

Non-pregnant women, age 18-50
- For study purposes, evidence of negative pregnancy is accounted for by the treating physician's initiation of treatment with oral anticoagulants
Objectively diagnosed VTE or atrial fibrillation/flutter
Patient reported active menstruation - does not apply to women who were recently pregnant
Clinical plan and patient agreement to treat with oral anticoagulation for 3 months or longer
Patients must have a working telephone

Exclusion Criteria

Package insert exclusions for Eliquis (Apixban) or Xarelto (Rivaroxaban): [active pathological bleeding or severe hypersensitivity reaction to XARELTO or ELIQUIS (e.g., anaphylactic reactions)]
Plan to become pregnant in the next three months.
Concomitant prescribed use of aspirin or thienopyridenes or other platelet inhibiting drugs
Plan for surgical hysterectomy or endometrial ablation
Known uterine cancer
Von Willebrand's disease, or hemophilia
Known coagulopathy from liver disease
Conditions likely to preclude adherence to study procedures: Active intravenous drug use, known alcoholism, homelessness, or uncontrolled psychiatric illness.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Apixaban	Apixaban	-
Rivaroxaban	Rivaroxaban	-

Primary Outcome Measures

Name	Time	Method
PBAC Scores	3 months	Measure Description: A PBAC Score of \< 100 indicates a normal menstrual cycle. The lowest possible score would be zero. Higher values indicate worse outcomes. The higher theoretical range value cannot be calculated. The scoring mechanism is as follows; Towels * 1 point for each lightly stained towel * 5 points or each moderately soiled towel * 20 points if the towel is completely saturated with blood Tampons * 1 point for each lightly stained tampon * 5 points for each moderately soiled tampon * 10 points if the tampon is completely saturated with blood Clots * 1 point for small clots * 5 points for large clots

Secondary Outcome Measures

Name	Time	Method
Number of Participants Who Crossed Over to Another Anticoagulant	3 months
Number of Participants With Clinically Relevant Non-major Bleeding	3 months
Number of Participants With Venous Thromboembolism (VTE)	3 months
Number of Participants Who Discontinued Planned Drug Administration	3 months
Number of Patients That Held Drug for Menorrhagia	1, 2, and 3 months
Number of Participants With Major Hemorrhage	3 months
Hemoglobin Concentration	3 months	Measure Description: Normal hemoglobin range for adult women - 12 - 16 g/dL. Lower levels indicate worse outcomes.
Physical Component Summary of Standard From 36	3 months	The RAND 36-Item Health Survey (Version 1.0) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively.

Trial Locations

Locations (2): Eskenazi Health System
🇺🇸
Indianapolis, Indiana, United States
Indiana University Health Methodist Hospital
🇺🇸
Indianapolis, Indiana, United States